Abstract Library

#4651 Neuroendocrine hyperplasia of infancy (NEHI) vs. diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH): What is the difference?

Introduction: Neuroendocrine Hyperplasia of Infancy (NEHI) is a rare disease that belongs to the group of interstitial lung disease in children; characterised by hypoxemia, tachypnoea, and respiratory distress, often misdiagnosed as reactive airway disease or bronchiolitis. The diagnosis relies on histologic evaluation. We describe the clinical presentation and paraclinical characteristics of paediatric patients with NEHI.

Conference:

Presenting Author:

Authors: González Devia D, Restrepo Gualteros S, Ortiz Pérez M, Fernández Hernández B,

Keywords: Neuroendocrine Hyperplasia of Infancy, Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia, child,

#4303 Carcinoid crisis: Insights from an ENETS Center of Excellence

Introduction: Neuroendocrine neoplasms (NENs) are rare tumours, with up to 30% being functional and associated with carcinoid syndrome (CS). CS commonly presents with flushing, diarrhoea, and hemodynamic instability, and can progress to carcinoid crisis (CC), a severe, potentially fatal complication during surgery or other invasive procedures. The use of prophylactic octreotide infusion peri-operatively remains controversial. The lack of a universal CC definition also poses a challenge for standardised outcome assessments.

Conference:

Presenting Author: Del Olmo-Garcia M

Authors: Del Olmo-Garcia M, Kong G, Wong H, Michael M, Ismail H,

Keywords: carcinoid syndrome, carcinoid crisis, somatostatin analogue, peri-operative management,

#4009 Hepatic metastatic model establishment of pancreatic neuroendocrine tumor by hemi-splenectomy

Introduction: The early diagnosis of pancreatic neuroendocrine tumor (pNET) patients is hard, and 60% patients are diagnosed with liver metastasis at the first visit to hospital. These patients are not suitable for surgery, which is the preferred and most effective option for pNETs. And liver metastasis promises worse outcome for patients.

Conference:

Presenting Author: Wang F

Authors: Wang F, Jing D, Zhou C, Qin Y, Chen J,

Keywords: Pancreatic neuroendocrine tumor, liver metastases, murine model, hemi-splenectomy, hepatic metastatic model,

#3934 The stromal microenvironment endows pancreatic neuroendocrine tumors with spatially specific invasive and metastatic phenotypes

Introduction: Cancer-associated fibroblasts (CAFs) play an important role in a variety of cancers. However, the heterogeneity of CAFs is poorly understood in non-functional pancreatic neuroendocrine tumors (NF-PanNETs). Profiling the heterogeneity of CAFs might reveal the causes of malignant phenotypes in NF-PanNETs.

Conference:

Presenting Author: Ye Z

Authors: Ye Z, Zhou C, Xu X, Chen J, Yu X,

Keywords: nonfunctional pancreatic neuroendocrine tumors, TGF-β, epithelial-mesenchymal transition,

#3714 CT derived body composition index analysis in metastatic NET patients treated with mTOR inhibitor

Introduction: Neuroendocrine tumors (NETs) are rare neoplasms frequently characterized by an upregulation of the mammalian rapamycin targeting (mTOR) pathway resulting in uncontrolled cell proliferation. The mTOR pathway is also involved in skeletal muscle protein synthesis and in adipose tissue metabolism. Everolimus inhibits the mTOR pathway, resulting in blockade of cell growth and tumor progression.

Conference:

Presenting Author: Fatima A

Authors: Fatima A,

Keywords: mTOR, metastatic NET, body composition index, skeletal muscle protein,